Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

@article{FerraroPeyret2004InfliximabTI,
  title={Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study},
  author={Carole Ferraro-Peyret and Fabienne Coury and Jacques Guy Tebib and Jacques Bienvenu and Nicole Fabien},
  journal={Arthritis Research & Therapy},
  year={2004},
  volume={6},
  pages={R535 - R543}
}
Treatment of rheumatoid arthritis (RA) with infliximab (Remicade) has been associated with the induction of antinuclear autoantibodies (ANA) and anti-double-stranded DNA (anti-dsDNA) autoantibodies. In the present study we investigated the humoral immune response induced by infliximab against organ-specific or non-organ-specific antigens not only in RA patients but also in patients with ankylosing spondylitis (AS) during a two-year followup. The association between the presence of… CONTINUE READING
45 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…